Industry news

WHO adopts new safety needle policy, calling smart syringes an 'urgent priority'

Michael Gibney / FierceDrugDelivery

Citing rampant use of the same needle to inject more than one person, the World Health Organization has--some might say finally--launched a new policy to make unsafe injections less prevalent. Part of this policy involves adopting up-to-date measures in syringe engineering, promoting the use of "smart" needles with precautions against unsafe use.

Can Neil Woodford reignite the U.K.'s taste for biotech investments?

John Carroll / FierceBiotech

High-profile investment guru Neil Woodford has rolled out his $300 million investment vehicle in the U.K., looking to attract a host of small investors behind a publicly traded trust that has big plans for investing in a new wave of small biotechs.

Creating a Culture of Trust & Breakthrough Innovation in Pharma

Bart Sayle Nick Hawker / eyeforpharma

Today’s pharma industry is suffering a crisis of trust. To thrive in this new environment, top leaders will not only have to develop innovative patient-centered models, they will also need to achieve enterprise-wide culture change and facilitate breakthrough innovation.

Top 10 drug brands by payments to doctors

Tracy Staton, FeircePharmaMarketing

The criticism was inevitable when the U.S. government rolled out its first batch of Sunshine Act data in October. Drugmakers and doctors had already been grousing about omitted entries and misleading info. We at FiercePharma had our own selfish complaint: The Open Payments database is monstrous--way too large for us to download and analyze with our paltry computing power.

Personalized Medicine: The Future of Health Care is Here Today

Peter Winter / BioWorld

Precision medicine has been capturing the headlines big time in the past couple of weeks with major initiatives being created in the U.S. and the UK. Their objective is to marshal resources to be able to accelerate the discovery and delivery of targeted therapies to patients more effectively.

Report lays out vision for enhancing postmarket monitoring of medical devices

Varun Saxena / FierceMedicalDevices

The Brookings Institute laid out its vision of a comprehensive medical device postmarket surveillance system in a report to various device industry stakeholders. The report's ideas were further detailed and debated during a series of moderated discussions at the think tank featuring the CEOs of Medtronic ($MDT) and Edwards Lifesciences ($EW), and the head of FDA's device arm, CDRH.

The 10 largest med tech M&A deals announced in 2014

Varun Saxena / FierceMedicalDevices

The summer of med tech (and pharma) merger mania certainly broadened our lexicon. It also transformed the medical device industry.

25 February 2015

Epic Sciences Appoints Chris Bernard as Chief Commercial Officer

Epic Sciences announced today the appointment of Chris Bernard as chief commercial officer. Mr. Bernard has more than 20 years of experience as a senior executive and company officer leading sales and marketing teams to build biopharma and translational research partnerships and commercialize IVD platforms. 

The healthcare system and medical device market in Russia

PRNewswire

This TforG report helps businesses gain a unique insight into the socio-economic dynamics in Russia until 2015, and helps analyze how they affect healthcare systems and their evolution. It can serve as an essential tool for sales, marketing, R&D and business managers with industry related interests.
 

Data Snapshot: Dwarfed By Big Pharma, Biotech By The Numbers

Bruce Booth / Forbes

Biotech fills the news these days – whether it’s the announcement of exciting new clinical data, another high-flying IPO, or a big M&A deal. Amidst the significant “share of voice” in the coverage of young and emerging biotech in the media, it’s easy to forget the relative scale of the sector relative to larger BioPharma companies.